No Prescription |
 |
 | ||
|
Alpha Index P |
|
| ||
|
No Prescription » Products » Alpha Index P
List of Drugs: A B C D E F G H I K L M N O P Q R S T U V W X Z # Products P: Panadol Cold Flu Hot Lemon Generic Tylenol Panadol Cold Flu Max Hot Lemon Generic Tylenol Panadol Rapid Soluble Tabs Tylenol PARLODEL Generic Bromocriptine PERSANTIN Generic Dipyridamole Plavix Generic Clopidogrel bisulfate Postinor 2 Generic Levonorgestrel Prednol Generic Methylprednisolone Premarin Vaginal Cream Generic Conj Estrogen PRO BANTHINE Generic Propantheline Proctofoam HC GB Hydrocortisone acetate Promensil Generic Red Clover Isoflavones Propine Generic Dipivefrin Hcl Pulmicort Inhaler Generic Budesonide Pulmicort respules Generic Budesonide Pulmicort Turbuhaler Generic Budesonide PURINETHOL Generic Mercaptopurine No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|